Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation

Sponsor
Fresenius Medical Care Deutschland GmbH
Study ID
NCT07679568
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Kidney Injury
  • Renal Failure

Eligibility Criteria

Sex
ALL
Age
1 Year - N/A
Healthy Volunteers
Not accepted

Interventions

  • multiFlux 160 hemofilter with regional heparin anticoagulation — DEVICE
    Extracorporeal blood purification with the multiFlux 160 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)
  • multiFlux 160 hemofilter with RCA with regional citrate anticoagulation — DEVICE
    Extracorporeal blood purification with the multiFlux 160 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)
  • multiFlux 130 hemofilter with regional heparin anticoagulation — DEVICE
    Extracorporeal blood purification with the multiFlux 130 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)
  • multiFlux 130 hemofilter with RCA with regional citrate anticoagulation — DEVICE
    Extracorporeal blood purification with the multiFlux130 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)
  • multiFlux 60 hemofilter with regional heparin anticoagulation — DEVICE
    Extracorporeal blood purification with the multiFlux 60 hemofilter during continuous kidney replacement therapy with RCA systemic heparin anticoagulation for patients suffering from acute kidney injury (AKI)
  • multiFlux 60 hemofilter with RCA with regional citrate anticoagulation — DEVICE
    Extracorporeal blood purification with the multiFlux 60 hemofilter during continuous kidney replacement therapy with RCA using 4% citrate with Ci-Ca dialysate (without gas barrier) for patients suffering from acute kidney injury (AKI)

Study Details

The goal of this observational study is to assess the performance of the multiFlux hemofilterwith regional or systemic anticoagulation during CKRT treatments. The multiFlux hemofilter is a single use device within the extracorporeal blood circuit during extracorporeal blood purification treatments for acute renal replacement therapies.

Key Dates

First listed
Jul 1, 2026
Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
62 participants (estimated)

Arms

  • Arm: AKI patients
    Patients with acute Kidney Injury (AKI) with clinical indication for CKRT

Primary Outcome Measure

Rate of clearance (Creatinine reduction in blood and effluent) as therapy efficacy at specified time points [ Time Frame: From enrollment up to 10 days ]

Central Contacts

Related Studies